Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 7/2016

01-07-2016 | Original Article

The attenuation of epithelial to mesenchymal transition and induction of anoikis by gigantol in human lung cancer H460 cells

Authors: Thitita Unahabhokha, Pithi Chanvorachote, Varisa Pongrakhananon

Published in: Tumor Biology | Issue 7/2016

Login to get access

Abstract

Lung cancer has been the major cause of death within patients due to the high metastatic rate. One of the most essential processes of metastasis is the ability of cancer cells to resist the programmed cell death in a detached condition called anoikis. The discoveries of new natural compound that is able to sensitize anoikis in cancer cells have garnered the most interest in cancer pharmaceutical science. Gigantol, a bibenzyl compound extracted from Dendrobium draconis, has been a promising natural derived compound for cancer therapy due to several cytotoxic effects in cancer cells. This study has demonstrated for the first time that gigantol significantly decreases lung cancer cells’ viability in a detached condition through anoikis and anchorage-independent assays. Western blotting analysis reveals that gigantol greatly decreases epithelial to mesenchymal transition (EMT) markers including N-cadherin, vimentin, and Slug leading to a significant suppression of protein kinase B (AKT), extracellular signal-regulated kinase (ERK), and caveolin-1 (cav-1) survival pathways during the detached condition. Therefore, gigantol could be a potential cancer therapeutic compound suggesting for further development for cancer therapy.
Literature
1.
Chiarugi P, Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol. 2008;76(11):1352–64.PubMedCrossRef
2.
Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. BBA Mol Cell Res. 2013;1833(12):3481–98.
3.
Guadamillas MC, Cerezo A, del Pozo MA. Overcoming anoikis—pathways to anchorage-independent growth in cancer. J Cell Sci. 2011;124(19):3189–97.PubMedCrossRef
4.
5.
Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ. 2008;16(1):3–11.PubMedPubMedCentralCrossRef
6.
Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28(1–2):15–33.PubMedCrossRef
7.
Sabbah M, Emami S, Redeuilh G, Julien S, Prévost G, Zimber A, et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat. 2008;11(4–5):123–51.PubMedCrossRef
8.
Shi Y, Wu H, Zhang M, Ding L, Meng F, Fan X. Expression of the epithelial-mesenchymal transition-related proteins and their clinical significance in lung adenocarcinoma. Diagn Pathol. 2013;8(1):1–1.
9.
Geiger TR, Peeper DS. Metastasis mechanisms. BBA Rev Cancer. 2009;1796(2):293–308.
10.
Voulgari A, Pintzas A. Epithelial–mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. BBA Rev Cancer. 2009;1796(2):75–90.
11.
12.
Floor SL, Dumont JE, Maenhaut C, Raspe E. Hallmarks of cancer: of all cancer cells, all the time? Trends Mol Med. 2012;18(9):509–15.PubMedCrossRef
13.
Powan P, Chanvorachote P. Nitric oxide mediates cell aggregation and mesenchymal to epithelial transition in anoikis-resistant lung cancer cells. Mol Cell Biochem. 2014;393(1–2):237–45.PubMedCrossRef
14.
Chanvorachote P, Pongrakhananon V, Halim H. Caveolin-1 regulates metastatic behaviors of anoikis resistant lung cancer cells. Mol Cell Biochem. 2014;399(1–2):291–302.PubMed
15.
Halim H, Luanpitpong S, Chanvorachote P. Acquisition of anoikis resistance up-regulates caveolin-1 expression in human non-small cell lung cancer cells. Anticancer Res. 2012;32(5):1649–58.PubMed
16.
Ravid D, Maor S, Werner H, Liscovitch M. Caveolin-1 inhibits anoikis and promotes survival signaling in cancer cells. Adv Enzyme Regul. 2006;46(1):163–75.PubMedCrossRef
17.
Ho C-C, Huang P-H, Huang H-Y, Chen Y-H, Yang P-C, Hsu S-M. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol. 2010;161(5):1647–56.CrossRef
18.
Chunhacha P, Chanvorachote P. Roles of caveolin-1 on anoikis resistance in non small cell lung cancer. Int J Physiol. 2011;4(3):149–55.
19.
Chanvorachote P. Epithelial-mesenchymal transition mediates anoikis resistance and enhances invasion in pleural effusion-derived human lung cancer cells. Oncol Lett. 2013;5:1043–47.PubMedPubMedCentral
20.
Klongkumnuankarn P, Busaranon K, Chanvorachote P, Sritularak B, Jongbunprasert V, Likhitwitayawuid K. Cytotoxic and antimigratory activities of phenolic compounds from dendrobium brymerianum. J Evid Based Complementary Altern Med. 2015;1–9.
21.
Charoenrungruang S, Chanvorachote P, Sritularak B. Gigantol-induced apoptosis in lung cancer cell through mitochondrial-dependent pathway. TJPS. 2014;38:67–73.
22.
Charoenrungruang S, Chanvorachote P, Sritularak B, Pongrakhananon V. Gigantol, a bibenzyl from Dendrobium draconis, inhibits the migratory behavior of non-small cell lung cancer cells. J Nat Prod. 2014;77(6):1359–66.PubMedCrossRef
23.
Sritularak B, Anuwat M, Likhitwitayawuid K. A new phenanthrenequinone from Dendrobium draconis. J Asian Nat Prod Res. 2011;13(3):251–5.PubMedCrossRef
24.
Bailey KM, Liu J. Caveolin-1 up-regulation during epithelial to mesenchymal transition is mediated by focal adhesion kinase. J Biol Chem. 2008;283(20):13714–24.PubMedPubMedCentralCrossRef
25.
Ha G-H, Park J-S, Breuer E-KY. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways. Cancer Lett. 2013;332(1):63–73.PubMedCrossRef
26.
27.
Weigelt B, Peterse JL, van’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591–602.PubMedCrossRef
28.
Baum B, Settleman J, Quinlan MP. Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol. 2008;19(3):294–308.PubMedCrossRef
29.
Larue L, Bellacosa A. Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 2005;24(50):7443–54.PubMedCrossRef
30.
Winitthana T, Lawanprasert S, Chanvorachote P. Triclosan potentiates epithelial-to-mesenchymal transition in anoikis-resistant human lung cancer cells. PLoS ONE. 2014;9(10), e110851.PubMedPubMedCentralCrossRef
31.
Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131–42.PubMedCrossRef
32.
Nurwidya F, Takahashi F, Murakami A, Takahashi K. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat. 2012;44(3):151–6.PubMedPubMedCentralCrossRef
33.
Frisch SM, Schaller M, Cieply B. Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J Cell Sci. 2013;126(1):21–9.PubMedPubMedCentralCrossRef
34.
35.
Enomoto A, Murakami H, Asai N, Morone N, Watanabe T, Kawai K, et al. Akt/PKB regulates actin organization and cell motility via girdin/APE. Dev Cell. 2005;9(3):389–402.PubMedCrossRef
36.
Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9(1):59–71.PubMedCrossRef
37.
38.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. BBA Mol Cell Res. 2007;1773(8):1263–84.
39.
Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2012;9–18.
40.
Luanpitpong S, Talbott SJ, Rojanasakul Y, Nimmanit U, Pongrakhananon V, Wang L, Chanvorachote P. Regulation of lung cancer cell migration and invasion by reactive oxygen species and caveolin-1. J Biol Chem. 2010;38832–40.
41.
Scheel C, Weinberg RA. Cancer stem cells and epithelial–mesenchymal transition: concepts and molecular links. Semin Cancer Biol. 2012;22(5–6):396–403.PubMedCrossRef
42.
Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.PubMedPubMedCentralCrossRef
43.
44.
Lobo NA, Shimono Y, Qian D, Clarke MF. The Biology of Cancer Stem Cells. Annu Rev Cell Dev Biol. 2007;23(1):675–99.PubMedCrossRef
45.
Yongsanguanchai N, Pongrakhananon V, Mutirangura A, Rojanasakul Y, Chanvorachote P. Nitric oxide induces cancer stem cell-like phenotypes in human lung cancer cells. Am J Physiol. 2015;308(2):89–100.CrossRef
46.
Chen K, Huang YH, Chen JL. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Nat Commun. 2013;34(6):732–40.
47.
Han L, Shi S, Gong T, Zhang Z, Sun X. Cancer stem cells—therapeutic implications and perspectives in cancer therapy. Acta Pharm Sin B. 2013;3(2):65–75.CrossRef
48.
Jung H-Y, Yang J. Unraveling the TWIST between EMT and cancer stemness. Stem Cells. 2015;16(1):1–2.CrossRef
49.
Schmidt JM, Panzilius E, Bartsch HS, Irmler M, Beckers J, Kari V, et al. Stem-cell-like properties and epithelial plasticity arise as stable traits after transient twist1 activation. Cell Rep. 2015;10(2):131–9.PubMedCrossRef
50.
Rajendran G, Dutta D, Hong J, Paul A, Saha B, Mahato B, et al. Inhibition of protein kinase C signaling maintains rat embryonic stem cell pluripotency. J Biol Chem. 2013;288(34):24351–62.PubMedPubMedCentralCrossRef
51.
Bhummaphan N, Chanvorachote P. Gigantol suppresses cancer stem cell-like phenotypes in lung cancer cells. J Evid Based Complement Altern Med. 2015;2015(3):1–10.CrossRef
Metadata
Title
The attenuation of epithelial to mesenchymal transition and induction of anoikis by gigantol in human lung cancer H460 cells
Authors
Thitita Unahabhokha
Pithi Chanvorachote
Varisa Pongrakhananon
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4717-z

Other articles of this Issue 7/2016

Tumor Biology 7/2016 Go to the issue

Original Article

CASP 3 genetic polymorphisms and risk of Hepatocellular carcinoma: a case-control study in a Chinese population

Original Article

Correlations of fascin-1 and cadherin-17 protein expression with clinicopathologic features and prognosis of patients with gastric cancer

Original Article

The far-upstream element-binding protein 2 is correlated with proliferation and doxorubicin resistance in human breast cancer cell lines

Original Article

Low expression of fibulin-1 correlates with unfavorable prognosis in gastric cancer

Original Article

Neferine induces autophagy of human ovarian cancer cells via p38 MAPK/ JNK activation

Original Article

Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits